S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
Log in
NASDAQ:AXDX

Accelerate Diagnostics Stock Forecast, Price & News

$9.88
-1.23 (-11.07 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.85
Now: $9.88▼
$11.18
50-Day Range
$9.98
MA: $11.08▼
$12.35
52-Week Range
$4.53
Now: $9.88▼
$19.11
Volume248,511 shs
Average Volume387,001 shs
Market Capitalization$556.79 million
P/E RatioN/A
Dividend YieldN/A
Beta2.54
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Read More
Accelerate Diagnostics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.71 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
Previous Symbol
CUSIPN/A
CIK727207
Webacceleratediagnostics.com
Phone520-365-3100
Employees287

Debt

Debt-to-Equity RatioN/A
Current Ratio10.13
Quick Ratio9.27

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.30 million
Price / Sales59.87
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.14) per share
Price / Book-70.57

Profitability

EPS (Most Recent Fiscal Year)($1.55)
Net Income$-84,310,000.00
Net Margins-803.60%
Return on Equity-5,681.44%
Return on Assets-63.72%

Miscellaneous

Outstanding Shares56,355,000
Market Cap$556.79 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$9.88
-1.23 (-11.07 %)
(As of 10/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

How has Accelerate Diagnostics' stock price been impacted by Coronavirus (COVID-19)?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AXDX stock has decreased by 6.9% and is now trading at $9.88.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Accelerate Diagnostics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Accelerate Diagnostics.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Accelerate Diagnostics.

How can I listen to Accelerate Diagnostics' earnings call?

Accelerate Diagnostics will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) released its quarterly earnings results on Thursday, August, 6th. The medical research company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.01. The medical research company earned $2.13 million during the quarter, compared to analysts' expectations of $2.47 million. Accelerate Diagnostics had a negative return on equity of 5,681.44% and a negative net margin of 803.60%.
View Accelerate Diagnostics' earnings history.

What price target have analysts set for AXDX?

3 analysts have issued 12 month price objectives for Accelerate Diagnostics' stock. Their forecasts range from $18.00 to $20.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $19.00 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics.

Who are some of Accelerate Diagnostics' key competitors?

Some companies that are related to Accelerate Diagnostics include Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), BioNano Genomics (BNGO), Eyepoint Pharmaceuticals (EYPT), Precipio (PRPO), HTG Molecular Diagnostics (HTGM), BioForce Nanosciences (BFNH), Astrotech (ASTC), Scientific Industries (SCND), Pressure Biosciences (PBIO), Arrayit (ARYC), DiaSys (DYXC) and Horiba (HRIBF).
View all competitors.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), MagnaChip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:
  • Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
  • Mr. Steve Reichling, Chief Financial Officer (Age 41)
  • Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
  • Mr. Kurt Reinhardt, Head of Operations
  • Dr. Romney M. Humphries, Chief Scientific Officer (Age 38)

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by many different retail and institutional investors. Top institutional investors include Chicago Capital LLC (3.49%) and Trellus Management Company LLC (0.08%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Romney Humphries, Steven Reichling and Thomas D Brown.
View institutional ownership trends for Accelerate Diagnostics.

Which institutional investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Trellus Management Company LLC.
View insider buying and selling activity for Accelerate Diagnostics.

Which institutional investors are buying Accelerate Diagnostics stock?

AXDX stock was bought by a variety of institutional investors in the last quarter, including Chicago Capital LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling, and Thomas D Brown.
View insider buying and selling activity for Accelerate Diagnostics.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $9.88.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $556.79 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]

This page was last updated on 10/21/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.